Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinsons' disease

Movement Disorders

Volumn 24, Issue 2, 2009, Pages 246-253

  Filipović, Saša R ^a   Rothwell, John C ^b   van de Warrenburg, Bart P ^b,c   Bhatia, Kailash ^b  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dyskinesia; Parkinson's disease; Placebo; Transcranial magnetic stimulation

Indexed keywords

AMANTADINE; CABERGOLINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DYSKINESIA; DYSTONIA; FEMALE; HUMAN; INTERVENTION STUDY; MALE; MORNING DOSAGE; MOTOR CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

AGED; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MEDICAL RECORDS; MIDDLE AGED; MOTOR CORTEX; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 61649083776     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22348     Document Type: Article

References (32)

1. Baas H. Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors, J Neurol 2000;247(Suppl 4):IV/12-IV/16.
2. Fabbrini G, Brotchie JM. Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389.
3. Koch G, Brusa L, Caltagirone C. et al. rTMS of supplementary motor area modulates therapy induced dyskinesias in Parkinson disease. Neurology 2005;65:623-625.
4. Brusa L, Versace V, Koch G, et al. Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease. Clin Neurophysiol 2006;117:1917-1921.
5. Wagle-Shukla A, Angel MJ. Zadikoff C, et al. Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias. Neurology 2007;69:704-705.
6. Damier P, Jaillon C, Clavier I, et al. Dyskinesia assessment in phase II studies. Mov Disord 1999;14 (Suppl 1): 54-59.
7. Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000;55:795-799.
8. Durif F, Vidailhet M, Debilly B, Agid Y. Worsening of levodopa-induced yskinesias by motor and mental tasks. Mov Disord 1999;14:242-245.
9. Hagell P, Widner H. Clinical rating of dyskinesias in parkinson's disease: use and reliability of a new rating scale. Mov Disord 1999;14:448-455.
10. Rossini PM, Barker AT. Berardelli A, et al. Non-invasive electrical and magnetic stimulation of the brain, spinal, cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1994;91:79-92.
11. Rothwell JC, Hallett M, Berardelli A, Eisen A, Rossini P, Paulus W. Magnetic stimulation: motor evoked potentials. The International Federation of Chnical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 1999,52:97-103.
12. Buhmann C, Glauche V, Sturenburg HJ, Oechsner M, Weiller C, Buchel C. Pharmacologically modulated fMRI - cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain 2003;126:451-461.
13. Haslinger B, Erhard P, Kampfe N, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001;124:558-570.
14. Sabatini U. Boulanouar K, Fabre N. et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000;123:394-403.
15. Rascol O, Sabatini U, Brefel C, et al. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain 1998;121:527-533.
16. Siebner HR, Filipovic SR, Rowe JB, et al. Patients with focal arm dystonia have increased sensitivity to slow-frequency repetitive TMS of the dorsal premotor cortex. Brain 2003:126:2710-2725.
17. Wenzelburger R, Zhang B-R, Pohle S. et al. Force overflow and levodopa-induced dyskinesias in Parkinson's disease. Brain 2002; 125:871-879.
18. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 2006;129:1059-1069.
19. Lefaucheur JP. Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: influence of Antiparkinsonian treatment and cortical stimulation. Clin Neurophysiol 2005; 116:244-253.
20. Filipovic SR, Heywood P, Rothwell JC, Bhatia K. Slow (1 Hz) repetitive transcranial magxetic stimulation (RTMS) induces sustained prolongation of silent period in patients with Parkinson's disease. Clin Neurophysiol 2006;117 (Suppl. 1):154.
21. Reis J, Johii D, Heimeroth A, et al. Modulation of human motor cortex excitability by single doses of amantadine. Neuropsychopharmacology 2006:31:2758-2766.
22. Pierantozzi M, Palmieri MG, Mazzone P, et al. Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study. Clin Neurophysiol 2002;113:108-113.
23. Young MS, Triggs WJ, Bowers D, Greer M, Friedman WA. Stereotactic pallidotomy lengthens the transcranial magnetic cortical stimulation silent period in. Parkinson's disease. Neurology 1997;49:1278-1283.
24. Cunic D, Roshan L, Khan FI, Lozano AM, Lang AE, Chen R. Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinson's disease. Neurology 2002;58:1665-1672.
25. Däuper J, Peschel T, Schrader C, et al. Effects of subthalamic nucleus (STN) stimulation on motor cortex excitability. Neurology 2002;59:700-706.
26. Sailer A, Cunic DI, Paradiso GO, et al. Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease. Neurology 2007;68:356-363.
27. Siebner HR, Auer C, Ceballos-Baumann A, Conrad B. Has repetitive transcranial magnetic stimulation of the primary motor hand area a therapeutic application in writer's cramp? Electroencephalogr Clin Neurophysiol Suppl 1999;51:265-275.
28. Siebner HR, Tormos JM, Ceballos-Baumann AO, et al. Low-frequency repetitive transcranial magnetic stimulation of the motor cortex in writer's cramp. Neurology 1999;52:529-537.
29. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology 2000;54:710-714.
30. de la Fuente-Fernández R. Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci 2002;25:302-306.
31. Fitzgerald PB, Brown TL, Daskalakis ZJ, Chen R, Kulkarni J. Intensity-dependent effects of 1 Hz rTMS, on human corticospinal excitability. Clin Neurophysiol 2002;113:1136-1141.
32. Mir P, Matsunaga K, Gilio F, Quinn NP, Siebner HR, Rothwell JC. Dopaminergic drugs restore facilitaitory premotor-motor interactions in Parkinson disease. Neurology 2005;64: 1906-1912.